SHEET _1 of 11

			<u> </u>
Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Auy, Docket No. 05569.0004.DVUS	Senat No New
INFORMATION DISCLOSU	IRE STATEMENT	Applicant McCafferty, J. et a	al.
(Use several sheets if nec		Filing Date 3-18-04	Group

	Τ		U.S. FA	TENT DOCUMENT	3		
*Examiner Initials		Document Number	Issue Date	. Name	Class	Subclass	Filing Date If Appropriate
	Al	4,593,002	06/03/86	Dulbecco	435	172.3	
	A2	4,816,397	03/28/89	Boss et al.	.435	68	
	A3	4,946,778	08/07/90	Ladner et al.	435	69.6	
	A4	5,091,513	02/25/92	Huston et al.	530	387	
	A5	5,223,409	06/29/93	Ladner et al.	435	69.7	
	A6	5,403,484	04/04/95	Ladner et al.	435	235.1	
	A7	5,427,908	06/27/95	Dower et al.	435	5	
-	A8	5,658,727	08/19/97	Barbas et al.	435	6	
	A9_	5,688,666	11/18/97	Bass et al.	435	69.4	
	A10	5,750,373	05/12/98	Garrard et al.	435	69.4	
	A11	5,759,817	06/02/98	Barbas, C.	435	69.7	
	A12	5,770,356	06/23/98	Light et al.	435	5	
	A13	5,780,279	07/14/98	Matthews et al.	435	172.3	
. ,	A14	5,821,047	10/13/98	Garrard et al.	435	5	
•	A15	5,846,765	12/08/98	Mätthew et al.	435	69.1	
	A16	5,849,500	12/15/98	Breitling et al.	435		
	A17	5.985.588	11/16/99	Breitling et al.	435	7.8	

EXAMINER	/Amber D. Steele/	DATE CONSIDERED 02/16/2010
*5.7.7.11715.0		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 2 of 11

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Any, Docket No. 05569.0004.DVUS	Serial New Sill Application	
INFORMATION DISCLOSUR	E STATEMENT	Applicant McCafferty, J. et al.		
(Use several sheets if neces.		Filing Date 3-18-04	Circup	

		FOR	REIGN PATE	ENT DOCUM	MENTS	_		
*Examiner		Document	Publication	Country	Class	Subclass	Trai	nslation
Initials		Number	Date	·	Class	Subclass	Yes	No
	B1	WO 83/02393	07/21/83	WIPO				
	B2	EP 2 137 631	10/10/84	EP				
	В3	EP 0 168 933	01/22/86	EP				
	B4	WO 88/06630	09/07/88	WIPO				
	B5	WO 88/09344	12/01/88	WIPO				
	B6	EP 0 324 162 A1	12/24/88	EP				
	В7	AU-B-27617/88	07/06/89	AU				
	В8	WO 90/02809	03/22/90	WIPO				-
· · · · · · · · · · · · · · · · · · ·	В9	WO 90/05144	05/17/90	WIPO	-			
-	B10	WO 90/14424	11/29/90	WIPO				
= 	B11	WO 90/14430	11/29/90	WIPO				······································
	B12	WO 90/14443	11/29/90	WIPO				
	B13	WO 91/10737	07/25/91	WIPO				
· 	B14	WO 91/17271	11/14/91	WIPO				
	B15	WO 92/06204	04/16/92	WIPO	:			. •
	B16	WO 92/09690	06/11/92	WIPO				
	B17	WO 92/18619	10/29/92	WIPO				· · · · · · ·

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
 Cl	Amit, A.G. et al., "Three-Dimentional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (August, 1986).

EXAMINER	/Amber D. Steele/	DATE CONSIDERED 02/16/2010
*EVAMINED I		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 3 of 11.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Auy. Docker No. 05569.0004.DVUS	Settat \ New Application	
INFORMATION DISCLOSU	SHRE STATEMENT	Applicant McCafferty, J. et al.		
(Use several sheets if	·	Filing Date 3-18-04	Group	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C2	Armstrong, J. et al., "Domain Structure of Bacteriophage fd Adsorption Protein," FEBS Lett., 135(1):167-172 (November, 1981).
C3	Bass et al., "Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties," <i>Proteins: Structure, Function and Genetics</i> , 8:309-314 (1990).
C4	Beck, E. et al., "Nucleotide sequence and genome organisation of filamentous bacteriophages f1 and fd," Gene, 16:35-58 (1981).
C5	Beck, E. et al., "Nucleotide sequence of bacteriophage fd DNA," Nucleic Acids Research, 5(12):4495-4503 (1978).
C6	Berek, C. et al., "Molecular events during maturation of the immune response to oxazolone," <i>Nature</i> . 316:412-418 (August, 1985).
C7	Better, M. et al., "Escherichia coli Secretion of an Active Chimeric Antibody Fragment," Science, 240:1041-1043 (May, 1988).
C8	Bhat, T.N. et al., "Small rearrangements in structures of Fv and Fab fragments of antibody D1.3 on antigen binding," <i>Nature</i> , 347:483-485 (October, 1990).
C9	Bird, R.E. et al., "Single chain antibody variable regions," TIBTECH, 9:132-137 (April, 1991).
C10	Bird, R.E. et al., "Single-Chain Antigen-Binding Proteins," Science, 242:423-426 (October, 1988).
C11	Boeke, J.D. et al., "Effects of Bacteriophage f1 Gene III Protein on the Host Cell Membrane," Mol. Gen. Genet., 186:185-192 (1982).
C12	Boyle, W., "An Extension of the ⁵¹ Cr-Release Assay for the Estimation of Mouse Cytotoxins," <i>Transplantation</i> . 6(6):761-764 (1968).
C13	Branden, C. et al., in Introduction to Protein Structure, Garland Publishing, Inc., New York and London, pp.26-29 (1991).
C14	Brenna, O. et al., "Affinity-Chromatography Purification of Alkaline Phosphatase from Calf Intestine," <i>Biochem. J.</i> , 151:291-296 (1975).
C15	Brownstone, A. et al., "Biological Studies with an Iodine-Containing Synthetic Immunological Determinant 4-Hydroxy-3-iodo-5-nitrophenylacetic Acid (NIP) and Related Compounds," Immunology, 10:481-492 (1966)

EXAMINER	/Amber D. Steele/	DATE CONSIDERED	02/16/2010
		or not citation is in conformance with N lude copy of this form with next commu	

SHEET 4 of 11

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Aux. Docket No. 05569.0004.DVUS1	Schill No New Application
INFORMATION DISCLOSUR	E STATEMENT	Applicant McCafferty, J. et a	: :l
(Use several sheets if neces		Filing Date 3-18-04	Group

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C16	Brownstone, A. et al., "Chemical and Serological Studies with an Iodine-Containing Synthetic Immunological Determinant 4-Hydroxy-3-iodo-5-nitrophenylacetic Acid (NIP) and Related Compounds," Immunology: 10:465-479 (1966).
C17	Carter, P. et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" Nucl. Acids Res., 13(12):4431-4443 (1985).
C18	Casali, P. et al., "Human Monoclonals from Antigen-Specific Selection of B Lymphocytes and Transformation by EBV," <i>Science</i> . 234:476-479 (October, 1986).
C19	Chaidaroglou, A. et al., "Function of Arginine-166 in the Active Site of Escherichia coli Alakaline Phosphatase," Biochemistry, 27:8338-8343 (1988).
C20	Chang, C. N. et al., "Nuceotide sequence of the alkaline phosphatase gene of Escherichia coli," Gene, 44:121-125 (1986).
C21	Chaudhary, V.K. et al., "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci., USA</i> , 87:1066-1070 (February, 1990).
C22	Chiang, Y.L. et al., "Direct cDNA Cloning of the Rearranged Immunoglobulin Variable Region," BioTechniques. 7(4):360-366 (1989).
C23	Choo, Y. et al., "In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence," Nature. 372:642-645 (1994).
C24	Choo, Y. et al., "Selection of DNA binding sites for zinc fingers using rationally randomized DNA reveals coded interactions," <i>Proc. Natl. Acad. Sci., USA, 91</i> :11168-11172 (1994).
C25	Choo Y. et al., "Toward a code for the interactions of zinc fingers with DNA: Selection of randomized fingers displayed on phage," <i>Proc. Natl. Acad. Sci., USA</i> , 91:11163-11167 (1994).
C26	Chothia, C. et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins," J. Mol. Biol., 196:901-917 (1987).
C27	Chuchana, P. et al., "Definition of the human immunoglobulin variable lambda (IGLV) gene subgroups," Eur. J. Immunol., 20:1317-1325 (1990).
C28	Clackson, T. et al., "Sticky feet'-directed mutagenesis and its application to swapping antibody domains." Nucl. Acids Res., 17(24):10163-10170 (1989).

EXAMINER	/Amber D. Steele/	DATE CONSIDERED 02/16/2010
		not citation is in conformance with MPEP 609; Draw line through de copy of this form with next communication to applicant.

U.S. Department of Commerce

Patent and Trademark Office

Filing Date

3-18-04

SHEET_5_of_11

Aux. Docker No. Serial No. New

05569.0004.DVUSTI Application

Applicant

McCafferty, J. et al.

Group

INFORMATION DISCLOSURE STATEMENT

Form PTO-1449 (Modified)

(Use several sheets if necessary)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
C29	Cunningham, C. et al., "Antibody engineering - how to be human," Trends Biotechnology, 10(4):112-113 (April, 1992).	
C30	C30 Curti, B.D., "Physical Barriers to drug delivery in tumors," Critical Reviews in Oncology/Hematology, 14:29-39 (1993).	
C31	Cwirla, S.E. et al., "Peptides on phage: A vast library of peptides for identifying ligands," <i>Proc. Natl. Acad. Sci., USA</i> , 87:6378-6382 (1990).	
C32	De Bellis, D. et al., "Regulated expression of foreign genes fused to lac: control by glucose levels in growth medium," Nucl. Acids Res., 18(5):1311 (1980).	
C33	De la Cruz et al., "Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," J. Biol. Chem., 263(9):4318-4322 (1988).	
C34	Dildrop, R., "A new classification of mouse V _H sequences," <i>Immunol. Today</i> , 5(4):85-86 (1984).	
C35	Dillman, R.O., "Monoclonal Antibodies for Treating Cancer," Annals of Internal Medicine, 111:592-603 (1989).	
C36 Dower, W.J. et al., "High efficiency transformation of E. coli by high voltage electroporation," Nucl. Acids Res., 16(13):6127-6145 (1988).		
C37 Eckert, K.A. et al., "High fidelity DNA synthesis by the <i>Thermus aquaticus</i> DNA polymerase," <i>Nucl. Acids Res.</i> , 18(13):3739-3744 (1990).		
C38	Eisen, H.N., "Determination of Antibody Affinity For Haptens and Antigens by Means of Fluorescence Quenching," <i>Meth. Med. Res.</i> , 10:115-121 (1964).	
C39	Evan, G.I. et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product," Mol. Cell. Biol., 5(12):3610-3616 (December, 1985).	
C40	Fikes, J.D. et al., "Maturation of Escherichia coli Maltose-binding Protein by Signal Peptidase I in Vivo," J. Biological Chemistry, 265(6):3417-3423 (1990).	
C41	Galfrè, G. et al., "Preparation of Monoclonal Antibodies: Strategies and Procedures," Methods Enzymology, 73:3-46 (1981).	
C42	Gherardi, E. et al., "A single-step procedure for cloning and selection of antibody-secreting hybridomas," J. Immunol. Methods. 126:61-68 (1990).	

EXAMINER	/Amber D. Steele/	DATE CONSIDERED	02/16/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET_6 of 11

Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Any, Docket No. 05569.0004.DVUS1	Senal No New Application
INFORMATION DISCLOSURE STATEMENT	Applicant McCafferty, J. et al.	
(Use several sheets if necessary)	Filing Date 2	Group

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C43	Glockshuber, R. et al., "The Disulfide Bonds in Antibody Variable Domains: Effects on Stability, Folding in Vitro, and Functional Expression in Escherichia coli," <i>Biochemistry</i> , 31:1270-1279 (1992).
	Goldstein, G., "Overview of the Development of ORTHOCLONE OKT3: Monoclonal Antibody for Therapeutic Use in Transplantation," <i>Transplantation Proceedings, Vol. XIX, No. 2. Suppl. 1</i> :1-6 (April, 1987).	
	C45	Gorick, B.D. et al., "Three Epitpoes on the Human Rh Antigen D Recognized by ¹²⁵ I-Labelled Human Monoclonal IgG Antibodies," Vox. Sang., 55:165-170 (1988).
	C46	Gottesman, M.E. et al., "Transcription Antitermination by Bacteriophage Lambda N Gene Product," J. Mol. Biol., 140:57-75 (1980).
	C47	Grant, R.A. et al., "Structure of the Filamentous Bacteriophage f1," J. Biol. Chem., 256(1):539-546 (January, 1981).
	C48	Griffiths, G.M. et al., "Somatic mutation and the maturation of immune reponse to 2-phenyl oxazolone," <i>Nature</i> , 312:271-275 (1984).
platelet-derived growth factor receptor: Evidence for more than one receptor cla		Gronwald, R.G.K. et al., "Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: Evidence for more than one receptor class," <i>Proc. Natl. Acad. Sci., USA</i> , 85:3435-3439 (May, 1988).
	C50	Harper, M. et al., "Antigen Specificity and Cross-Reactivity of Monoclonal Anti- Lysozyme Antibodies," <i>Molec. Immunol.</i> , 24(2):97-108 (1987).
	C51	Harris, W.J. et al., "Therapeutic antibodies - the coming of age," <i>Trends Biotechnology,</i> 11:42-44 (February, 1993).
	C52	Hird, V. et al., "Immunotherapy with Monoclonal Antibodies," in Genes and Cancer, Edited by D. Carney and K. Sikora, John Wiley & Sons, Ltd., pp.183-189 (1990).
	C53	Horton, R.M. <i>et al.</i> , "Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension," <i>Gene.</i> 77:61-68 (1989).
	C54	Hughes-Jones, N.C. et al., "Nucleotide sequences and three-dimensional modelling of the V _H and V _L domains of two human monoclonal antibodies specific for the D antigen of the human Rh-blood-group system," <i>Biochem. J.</i> . 268:135-140 (1990).
	C55	Hull, W.E. et al., " ³¹ P Nuclear Magnetic Resonance Study of Alkaline Phosphatase: The Role of Inorganic Phosphate in Limiting the Enzyme Turnover Rate at Alkaline pH," Biochemistry, 15(7):1547-1561 (1976).

EXAMINER	/Amber D. Steele/	DATE CONSIDERED	02/16/2010
i			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET _7 of 11 _

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Any, Docket No 05569 . 0004 .1	DVUS1I	Schale New Application
INFORMATION DISCLOSUR	F STATEMENT	Applicant McCafferty, J. et al.		
(Use several sheets if necess		Filing Date 3-18-04	11	Group

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C56	Huse et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science, 246:1275-1281 (1989).
C57	Huston, J.S. et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci., USA, 85:5879-5883</i> (August, 1988).
C58	Izard, J.W. et al., "Signal peptides: exquisitely designed transport promoters," Molecular Microbiology, 13(5):765-773 (1994).
C59	Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. pgs.339, 362, 430, 451 and 1418 (1991).
C60	Kabat et al., Sequences of Proteins of Immunological Interest, 4th ed. p.181 (1987).
C61	Kang, A.S. et al., "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <i>Proc. Natl. Acad. Sci., USA, 88(24)</i> :1120-11123 (1991).
C62	Kang, A.S. et al., "Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces," <i>Proc. Natl. Acad. Sci., USA.</i> 88(10):4363-4366 (1991).
C63	Kettleborough, C.A. et al., "Humanization of a mouse antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> , 4(7):773-783 (1991).
C64	Kim, Y. et al., "Refinement of Eco RI Endonuclease Crystal Structure: A Revised Protein Chain Tracing," Science, 249:1307-1309 (1990).
C65	Köhler, G. et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , 256:495-497 (August, 1975).
C66	Kornberg, A., <i>DNA Replication</i> , W.H. Freem & Co., San Francisco, pp. 15, 20, 287, 385, 368-369, 383-385, 393, 461, 474, 478-496, 505-506 (1974).
C67	Laforet, G.A. et al., "Functional Limits of Conformation, Hydrophobicity, and Steric Constraints in Prokaryotic Signal Peptide Cleavage Regions," J. Biological Chemistry, 266(2):1326-1334 (1991).
C68	Larrick, J.W. et al., "Rapid Cloning of Rearranged Immunoglobulin Genes from Human Hybridoma Cells Using Mixed Primers and the Polymerase Chain Reaction," <i>Biochem. Biophys. Res. Commun.</i> , 160(3):1250-1255 (May, 1989).

EXAMINER	/Amber D. Steele/	DATE CONSIDERED 02/16/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 8 of 11

	ient of Commerce Trademark Office	Auy, Docker No. 05569 . 0004 . DVUS 1 1	Senat No New Application
INFORMATION DISCLOSURE STATI	STATEMENT	Applicant McCafferty, J. et al.	
(Use several sheets if necessary)		Filing Date 3-18-04	Group

	OTHER DOCUMENTS (L. L. L
<u> </u>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C69	Lesk, A. M. et al., "Elbow motion in the immunoglobulins involves a molecular ball-and -socket joint," <i>Nature</i> . 335:188-190 (September, 1988).
C70	Mäkelä, O. et al., "Inheritance of Antibody Specificity V Anti-2-Phenyloxazolone in the Mouse," J. Exp. Med., 148:1644-1660 (December, 1978).
C71	Malamy, M.H. et al., "Purification and Crystallization of the Alkaline Phosphatase of Escherichia coli," Biochemistry. 3(12):1893-1897 (December, 1964).
C72	Marvin, D.A. et al., "Molecular Models and Structural Comparisons of Native and Mutant Class I Filamentous Bacteriophages Ff m(fd, fl, M13), Ifl and IKe," J. Mol. Biol., 235:260-286 (1994).
C73	McCafferty et al., "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," Nature, 348:552-554 (1990).
C74	McCracken, S. et al., "Functional and Structural Properties of Immobilized Subunits of Escherichia coli Alkaline Phosphatase," J. Biol. Chem., 255(6):2396-2404 (March, 1980).
C75	Melamed, M.D. et al., "Requirements for the establishment of heterohybridomas secreting monoclonal human antibody to rhesus (D) blood group antigen," J. Immunological Methods. 104:245-251 (1987).
C76	Milstein F.R.S., C., "The Croonian Lecture, 1989 Antibodies: a paradigm for the biology of molecular recognition," <i>Proceedings of the Royal Society of London</i> , 239(1294):1-16 (1990)
C77	Munro, S. et al., "An Hsp70-like Protein in the ER: Identity with the 78 kd Glucose-Regulated Protein and Immunoglobulin Heavy Chain Binding Protein," Cell. 46:291-300 (July, 1986).
. C78	Nagai, K. et al., "Synthesis and Sequence-Specific Proteolysis of Hybrid Proteins Produced in Escherichia coli," Methods Enzymology, 153:461-481 (1987).
C79	Neuberger, M.S. et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , 312:604-608 (1984).
C80	Newman, A.K. et al., "DNA Sequences of Structural Genes for Eco RI DNA Restriction and Modification Enzymes," J. Biological Chemistry, 256(5):2131-2139 (1981).
C81	Ohlson, S. et al., "Novel Approach to Affinity Chromatography Using "Weak" Monoclonal Antibodies." Anal. Biochem., 169:204-208 (1988).

EXAMINER	/Amber D. Steele/	DATE CONSIDERED	02/16/2010
		or not citation is in conformance with M lude copy of this form with next commu	

SHEET 9 of 11

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Am. Docker No. 05569.0004.DVUS11	Senal No New Application
INFORMATION DISCLOSU	RF STATEMENT	Applicant McCafferty, J. et a.	: I
(Use several sheets if nec		Filing Date 3–18–04	Group

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C82	Offver, D.B. et al., "Periplasm and Protein Secretion," in Eschwichia cali and Salwanalla typhimurium: cellular and molecular biology, F.C. Neidhart (ed.), American Society for Microbiology, Washington, pp. 56-69.
C83	Orlandi, R. et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <i>Proc. Natl. Acad. Sci., USA, 86</i> :3833-3837 (May, 1989).
C84	Osband, M.E. et al., "Problems in the investigational study and clinical use of cancer immunotherapy," <i>Immunology Today</i> . 11(6):193-195 (1990).
C85	Parmley et al., "Antibody-selectable Filamentous fd Phage Vectors: Affinity Purification of Target Genes," <i>Gene</i> , 73(2):305-318 (December, 1988).
C86	Parmley, S.F. et al., "Filamentous Fusion Phage Cloning Vectors for the Study of Epitopes and Design of Vaccines," Adv. Exp. Med. Biol., 251:215-218 (1989).
C87	Perelson, A.S., "Immune Network Theory," Immunol. Reviews, 110:5-36 (1989).
C88	Pratt, D. et al., "Conditional Lethal Mutants of the Small Filamentous Coliphage M13 II. Two Genes for Coat Proteins," Virology, 39:42-53 (1969).
C89	Rasched, I. et al., "Ff Coliphages: Structural and Functional Relationships," Microbiological Reviews, 50(4):401-427 (1986).
C90	Riechmann, L. et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 332:323-327 (March, 1988).
C91	Rossomando, E.F. et al., "Studies on the Bacteriophage fl I. Alkali-induced Disassembly of the Phage into DNA and Protein," J. Mol. Biol., 36:387-399 (1968).
C92	Saiki, R.K. et al., "Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase," <i>Science</i> , 239:487-491 (January, 1988).
C93	Sambrook <i>et al.</i> , Molecular Cloning: A Laboratory Manual, 4.13-4.14, 4.17-4.19, 4.46 and A.12 (1989).
C94	Sastry, L. et al., "Cloning of the immunological repertoire in Escherichia coli for generation of monoclonal catalytic antibodies: Construction of a heavy chain variable region-specific cDNA library," Proc. Natl. Acad. Sci., USA, 86:5728-5732 (August, 1989).
C95	Schaaper, R.M. et al., "Escherichia coli mutT Mutator Effect during in Vitro DNA Synthesis," J. Biol. Chem., 262(34):16267-16270 (December, 1987).

	EXAMINER	/Amber D. Steele/	DATE CONSIDERED	02/16/2010
ı				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			STEET 10 OF 11
Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No 05569.0004.DVUS1	New Application
INFORMATION DISCLOSE	URE STATEMENT	Applicant McCafferty, J. et a	il.
(Use several sheets if ne		Filing Date 3–18–04	Group

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
,	C96	Schapper, R.M., "Mechanisms of mutagenesis in the <i>Escherichia coli</i> mutator mutD5: Role of DNA mismatch repair," <i>Proc. Natl. Acad. Sci., USA, 85</i> :8126-8130 (November, 1988).
	C97	Schneider, G. et al. "Analysis of Cleavage-Site Patterns in Protein Precursor Sequences with a Perceptron-Type Neural Network," Biochemical and Biophysical Research Communications, 194(2):951-959 (1993).
-	C98	Shimatake, H. et al., "Purified λ regulatory protein cII positively activates promoters for lysogenic development," <i>Nature</i> , 292:128-132 (July, 1981).
	C99	Short et al., "Lambda ZAP: A Bacteriophage Lambda Expression Vector with In Vivo Excision Properties," Nucleic Acids Research, 16(15):7583-7600 (August, 1988).
	C100	Skerra, A. et al., "Assembly of a Functional Immunoglobulin F, Fragment in Escherichia coli," Science, 240:1038-1040 (May, 1988).
	C101	Smith, G.P., "Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Virion Surface," <i>Science</i> . 228(4705):1315-1317 (June, 1985).
	C102	Smith, G.P., "Filamentous Phage Assembly: Morphogenetically Defective Mutants That Do Not Kill the Host," Virology, 167:156-165 (1988).
·	C103	Stanfield, R.L. et al., "Crystal Structures of an Antibody to a Peptide and Its Complex with Peptide Antigen at 2.8 Å," Science, 248:712-719 (1990).
	C104	Stengele, I. et al., "Dissection of Functional Domains in Phage fd Adsorption Protein Discrimination between Attachment and Penetration Sites," J. Mol. Biol., 212(1):143-149 (1990).
	C105	Strauch, K. L. et al., "An Escherichia coli mutation preventing degradation of abnormal periplasmic proteins," Proc. Natl. Acad. Sci., USA, 85:1576-1580 (March, 1988).
	C106	Tsunetsugu-Yokota et al., "Expression of an Immunogenic Region of HIV by a Filamentous Bacteriophage Vector," Gene. 99(2):261-265 (March, 1991).
	C107	Van Wezenbeek, P. et al., "Nucleotide sequence of the filamentous bacteriophage M13 DNA genome: comparison with phage fd," Gene. 11:129-148 (1980).
	C108	Venkitaraman, A.R., "Use of modified T7 DNA polymerase (sequence version 2.0 TM) for oligonucleotide site-directed mutagenesis," <i>Nucl. Acids Res.</i> , 17(8):3314 (April, 1989).

EXAMINER	/Amber D. Steele/	DATE CONSIDERED	02/16/2010	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		S	HEET II of 11
Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Any. Docker No 05569.0004.DVUS11	Senal No New Application
INFORMATION DISCLOS	SURE STATEMENT	Applicant McCafferty, J. et a	·
(Use several sheets if		Filing Date 3-18-04	Ciroup

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
	C109	Vieira, J. et al., "Production of Single-Stranded Plasmid DNA," Methods Enzymol., 153:3-11 (1987).	
	C110	Von Boehmer, H. et al., "The Separation of Different Cell Classes from Lymphoid Organs. IX. A Simple and Rapid Method for Removal of Damaged Cells From Lymphoid Cell Suspensions," J. Immunol. Methods, 2:293-301 (1973).	
	C111	Waldmann, T.A., "Monoclonal Antibodies in Diagnosis and Therapy." <i>Science</i> . 252:1657-1662 (June, 1991).	
	C112	Walter, G. et al., "Antibodies Against Synthetic Peptides," in Genetic Engineering: Principles and Methods, Vol. 5, Setlow and Hollaender (eds.), Plenum, New York, pp. 61-91 (1983).	
(C113	Ward, E.S. et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> . 341:544-546 (October, 1989).	
. (C114	Webster, R.E. et al., "Morphogenesis of the Filamentous Single-stranded DNA Phages," In: <i>The Single Stranded DNA Phages</i> , Cold Spring Harbor Laboratory Press, pp. 557-569 (1978).	
	C115	White, M. R. H. et al., "Imaging of Firefly Luciferase Expression in Single Mammalian Cells Using High Sensitivity Charge-Coupled Device Cameras," <i>Technique (PHILA), 2 (4)</i> 194-201 (1990).	
	C116	Williams, A.F. et al., "The Immunoglobulin Superfamily - Domains for Cell Surface Recognition". Ann. Rev. Immunol., 6:381-405 (1988).	
	C117	Winter et al., "Man-made Antibodies," Nature, 349(6307):293-299 (January, 1991).	
C	C118	Yanisch-Perron, C. et al., "Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors," <i>Gene.</i> 33:103-119 (1985).	
ſ	C119	Zacher III, A.N. et al., "A New Filamentous Phage Cloning Vector: fd-tet," Gene. 9:127-140 (1980).	

EXAMINER	/Amber D. Steele/	DATE CONSIDERED	02/16/2010
•		i	02/10/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (10-01

Approved for use through 10/31/2002. OMB 0651-003:

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet 1 of

Docket Number Application Number 05569.0004.DVUS11 **New Application** Substitute for form 1449A/PTO Applicant INFORMATION DISCLOSURE McCafferty et al. STATEMENT BY APPLICANT Filing Date Group Art Unit (Use several sheets if necessary) March 18, 2004 **U. S. PATENT DOCUMENTS EXAMINER** SUB FILING DATE DOCUMENT NUMBER CLASS INITIAL DATE NAME CLASS IF APPROP. A1 5 6 3 3 1 4 1 Cabilly et al. 435 69.6 6/10/88 A2 07/ 2 4 0 1 6 0 3/22/90 Ladner application 5 2 7 8 06/95 4 9 0 Dower et al. 435 5 6 1 7 2 1 9 7 01/01 McCafferty et al. 530/387 3 5 9 9 6 1 0 8 10/99 McCafferty et al. ' 530/387 3 FOREIGN PATENT DOCUMENTS Translation SUB DOCUMENT NUMBER DATE COUNTRY CLASS **CLASS** Yes No ВІ 3/10/88 WO 88/01649 **PCT B**2 10/19/90 Great Britain GB9022845.3 GB9024503.6 patent 83 Great Britain 11/12/90 application GB 9104744.9 patent RA Great Britain <u>appli</u>cation 3/6/91 85 EP-A-0 368 684 Great Britain 5/16/90 86 GB9015198.6 priority 7/10/90 Great Britain document В7 GB 9022845.3 priority 10/19/90 Great Britain document 88 GB 9104744.9 priority 3/6/91 Great Britain document В9 GB9110549.4 priority 5/15/91 Great Britain document B10 EP-B-0 349 578 B1 11/30/94 Great Britain OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) First Amended Complaint, Filed March 8, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (24 pages) (U.S. District Court, District of Columbia)(signed by John S. Skilton, Attorney for Plaintiff).) C2 Cambridge Antibody Technology Limited's Answer to First Amended Complaint, Filed March 22, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia)(signed by Brian H. Corcoran, Attorney for Defendant). **EXAMINER** /Amber D. Steele/ DATE CONSIDERED 02/16/2010 EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in

PTO/SB/08A (10-0)

Approved for use through 10/31/2002. OMB 0651-003 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Sheet _ 2 _ of _ 10

Substitute	for form 1449A/PTO	Docket Number 05569.0004.DVUS11	Application Num New Applicat	
	INFORMATION DISCLOSURE	Applicant McCafferty et al.		
Use sever	STATEMENT BY APPLICANT all sheets if necessary)	Filing Date March 18, 2004	Group Art Unit	
OTHER	DOCUMENTS (Including Author, Title, Date, Pe	ertinent Pages, Etc.)		
СЗ	ll'ichev, A.A., et al., "M13 Filamentous Bacteriophag	e in Protein Engineering", Molekuly	amaya Biologiya, Vol. 24, No. 2,	
	pp. 530-535, (March-April 1990).			
C4	lliychev, A.A., et al., "M13 Filamentous Bactioph	age for Protein Engineering", Ma	olekulyarnaya Biologiya, Vol. 24, No	
1	pp. 530-535, (March-April 1990). (In Russian with T	ranslated Abstract)		
C5	Redacted Agreement Between Medical Resea Cambridge	rch Council and Cambridge Anti	ibody Technology Limited and	
	Antibody Technology Group plc, made 01 January 1997			
C6	Deposition Transcript of David W. Clough, taker	April 19, 2002 (Morphosys AG v.	Cambridge Antibody Technology	
	Limited, U.S. District Court, Northern District of Illi	nois, Eastern Division).		
C7	E.I. du Pont de Nemours v. Cetus Corp., 19 USPG	02d 1174, (DC N.Cal. 1990).		
C8	OddzOn Products Inc. v. Just Toys Inc., 43 USPQ	2d 1641 (CAFC 1997).	,	
C9	Deposition Transcript of George P. Smi Cambridge Antibody Technology Limited	ith, Ph.D., taken 14 May 20 , Case No. 1:00-CV-00146 (3	02, Morphosys AG v. 30 pages)	
1	(U.S. District Court, District of Columbia.))		
C11	Deposition Transcript of Dr. David Chiswell, ta	aken 29 April 2002; Morphosys	AG v. Cambridge Antibody	
	Technology Limited, Case No. 1:00-CV-0014	6 (30 pages) (U.S. District Cour	t, District of Columbia.)	
C12	Deposition Transcript of Dr. Gregory Paul Winter, ta	ken April 30, 2002; Morphosys AG	v. Cambridge Antibody Technology	
	Limited, Case No. 1:00-CV-00146 (30 pages) (U.S.	District Court, District of Columbia.)		
C13	Vol. I - Deposition Transcript of Sean Malcolm	Walton, taken 01 May 2002, M	lorphosys AG v. Cambridge Antib	
	Technology Limited, Case No. 1:00-CV-00146	(30 pages) (U.S. District Court	, District of Columbia.)	
XAMINER	/Amber D. Steele/		DATE CONSIDERED 02/16	

PTO/SB/08A (10-01

Approved for use through 10/31/2002. OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet 3 of 10

	for form 1449A/PTO	Docket Number 05569.0004.DVUS11 Applicant	Application Number New Application	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	McCafferty et al.		
(Use several sheets if necessary)		Filing Date March 18, 2004	Group Art Unit	
OTHER I	DOCUMENTS (Including Author, Title, Date	e, Pertinent Pages, Etc.)		
C14	Vol. II - Deposition Transcript of Sean Malcolm	Walton, taken 02 May 2002, Morphosys AG	v. Cambridge Antibody	
	Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Col	umbia.)	
C15	Chiswell memo, dated 30 July 1990, transmitting	g a copy of the Collaborative Agreement bet	ween Cambridge Antibody	
┦	Technology and The Medical Research Council	, dated July 27, 1995.		
C16	Declaration of George P. Smith, Ph.D., Unde	er 37 C.F.R. § 1.132, executed 30 June 19	95 (submitted during the	
1 1	prosecution of U.S. Application No. 08/322,352).			
C17	Declaration of Brian K. Kay, Ph.D., executed	28 June 1998, (submitted during the pro	secution of European Appln.	
	No. 91913039.3)			
C18	Abstract of George P. Smith, Grant No. 1R01GN	M41478-01A1, Project Start Date: July 1, 198	9, Dept. of Health & Human	
	Services.			
C19	Smith Grant Application, entitled: "Filamentous Phage Physiology", dated November 1, 1988			
l [Thage Thyolology , dated the vernior T, 1000		
C20	Administration Agreement between Cambridge	73/7-10,116		
C20	Administration Agreement between Cambridge (Redacted).	73/7-10,116		
C20	-	Antibody Technology Ltd. and Medical Resea	arch Council, dated 01 August 1991	
	(Redacted).	Antibody Technology Ltd. and Medical Resea	arch Council, dated 01 August 1991	
	(Redacted). Fewfrom-John-MoSofforty-(of-Combridge-Aptible	Antibody Technology Ltd. and Medical Research	arch Council, dated 01 August 1991	
C21	(Redacted). For from John McCofforty (of Combridge Antibo	Antibody Technology Ltd. and Medical Research	arch Council, dated 01 August 1991	
C21	(Redacted). *Forefront-dolon/to-Combridge-Antibed the-Smith-great-opplication	Antibody Technology Ltd. and Medical Reserved	arch Council, dated 01 August 1991 Annies Ellis) segasting	
C21	(Redacted). For from John Macallacty (of Combridge Antibed Macallacty) (o	Antibody Technology Ltd. and Medical Reserved	arch Council, dated 01 August 1991 Annies Ellis) regesting	
C21	(Redacted). For from John McCofforty (of Combridge Antiboth Committee Commi	Antibody Technology Ltd. and Medical Research Market Second Welton (ed.) Market Second Welton (ed.) Midge Amilbody Technology Limited) to Brian	Acuber Ellic) regarding Hery regarding the Smith	
C21 C22 C23	(Redacted). For from John McCofforty (of Combridge Antiboth Smith grant application Committee grant application	Antibody Technology Ltd. and Medical Research Market Second Welton (ed.) Market Second Welton (ed.) Midge Amilbody Technology Limited) to Brian	Acuber Ellic) regarding	
C21 C22 C23	(Redacted). For from John McCafferty, Ph.D. (of Cambridge (Redacted). For from John McCafferty, Ph.D. (of Cambridge).	Antibody Technology Ltd. and Medical Reserved Technology Limited) to Soan Wolton (of Junior Antibody Technology Limited) to Brian from John McCarrenty (Cambridge Antibody Jechnology Limited) from Cro	Acubus Ellic) regarding Hery regarding the Smith Fechnology Emited) regarding the	
C21	(Redacted). For from John McCafferty (of Cambridge Antibed the Continues and Expelication. The Continues and Expelication. The Continues and Expelication. For to John McCafferty, Ph.D. (of Cambridge dated June 10, 1996.	Antibody Technology Ltd. and Medical Reserved Technology Limited) to Soan Wolton (of Junior Antibody Technology Limited) to Brian from John McCarrenty (Cambridge Antibody Jechnology Limited) from Cro	Acubus Ellic) regarding Hery regarding the Smith Fechnology Emited) regarding the	
C21	(Redacted). For from John McCafferty (of Combridge Antiboth Smith great application. Tentimessage from John McCafferty (of Cambridge Antiboth Smith great application. Fax to John McCafferty, Ph.D. (of Cambridge dated June 10, 1996. Smith, G. P., "1988 - A Year of Discovery", Ph.	Antibody Technology Ltd. and Medical Research Antibody Technology Limited) to Soon Walton (of Junior Antibody Technology Limited) to Brian from John McCamerty (Cambridge Antibody technology Limited) from Cropage Display of Peptides and Proteins, According Display Of Peptides Display Displa	Acubus Ellic) regarding Hery regarding the Smith Fechnology Emited) regarding the	
C21 C22 C23 C23A C24	(Redacted). For from John McCafferty (of Combridge Antibotion Tender message from John McCafferty (of Cambridge Antibotion Fax to John McCafferty, Ph.D. (of Cambridge dated June 10, 1996. Smith, G. P., "1988 - A Year of Discovery", Ph. pp. xvii-xix.	Antibody Technology Ltd. and Medical Reserved Antibody Technology Limited) to Soon Walton (of Medical Reserved) to Soon (of M	Assubuse Ellic) regarding. Hery regarding the Smith Permotogy Emitted) regarding the	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in

PTO/SB/08A (10-0)

Approved for use through 10/31/2002. OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Sheet 4 of 1

			Sneet_4
Substitut	e for form 1449A/PTO	Docket Number 05569.0004.DVUS11	Application Numb New Application
Substitut	INFORMATION DISCLOSURE	Applicant	I New Applicati
	STATEMENT BY APPLICANT	McCafferty et al.	
(Use several sheets if necessary)		Filing Date March 18, 2004	Group Art Unit
OTHER	DOCUMENTS (Including Author, Title, Date, Pe		
C27	Barbas and Lerner "Combinatorial Immunoglof	obulin Libraries on the surface of p	hage (Phabs): rapid select
	anti-specific fabs." Methods: a companion to	o methods in Enzymology Vol. 2 (2)	: 119-124 (1991).
C28	Interlocutory Decision in Opposition Proceedi	ings to the European Patent EP-B-0	9589877 dated April 15, 200
-	(reference number SMW/CP9503921)	· · · · · · · · · · · · · · · · · · ·	
C29	Notice of Appeal to the European Patent EP-	B-0589877 from Dyax Corp., filed Ju	une 17, 2002
C30	Communication from EPO on Notice of Appe	al filed by Dyax, issued October 2	1, 2002
C31	Notice of Appeal to the European Patent EP-	B-0589877 from BioInvent Therapeu	utic AB, filed June 14, 2002
C32	Appeal No. T0639/02-334 from BioInvent There August 22, 002	ppeutic AB to the European Patent	EP-B-0589877, filed,
C33	Notice of Appeal to the European Patent EP- Of the Appeal filed August 22, 2002	B-0589877 from MorphoSys AG filed	d June 20 2002 and Ground
C34	Notice of Appeal filed June 24, 2002 and Gro Technology Limited against the Decision of th		02 from Cambridge Antibo
C35	Notice of Opposition to the European Patent	EP-B-0589877 from BioInvent Intern	national AB, filed
-	October 24 2002	· · · · · · · · · · · · · · · · · · ·	The state of the s
C36	Docoment D80 in Appear No: 10839702-334. H	H3 Treedom of Information Act (F	OIA) regulations, table of
	centents, 5-4, 5-2, 5-3, 5-5, 5-24, 5-22, 5-24, 6-24	~ 6.32~6.33~6.34~5.35~5.54~6.44~en	d-6-6-6
C37	Docoment D01 in Apped No. 10439/02-224-5	mith-Declaration	 -
C38	Document 082 in Appeal the T0639/02 334 G	iopy of Grant Application GAA444	78-and-renewal-applicatio
	S <u>upplied by the Other</u>	· · · · · · · · · · · · · · · · · · ·	
EXAMINER	/Amber D. Steele/		DATE CONSIDERED 02/16/2010
	l: Initial if citation considered, whether or not citation and not considered. Include copy of this form with n		raw line through citation if not

Approved for use through 10/31/2002. OMB 0651-003 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet 5 of 1

Substitu	te for form 1449A/PTO	Docket Number 05569.0004.DVUS11	Application Number New Application	
	INFORMATION DISCLOSURE	Applicant McCafferty et al.		
(Use sev	STATEMENT BY APPLICANT eral sheets if necessary)	Filing Date	Group Art Unit	
	,,,	March 18, 2004	·	
OTHER	R DOCUMENTS (Including Author, Title, Date, Pe	ertinent Pages, Etc.)		
C39	Document D83 in Appeal No. T0639/02-334: Le	etter dated 26 August 1999 from Cambrid	ge Antibody	
	Technology Ltd in opposition proceedings against EP 0 527 839			
C40	Document D85 in Appeal No. T0639/02-334: Proprietor's letter of 12 November 1997 and amended claims			
C41	Document Daatin Appear No. 10637/02-334: EP 0774 311 XI			
		`		
C42	Document D87 in Appeal No. T0639/02-334: Proprietor's letter of 15 November 2000			
C43	Document D88 in Appeal No. T0639/02-334: Grounds of Appeal dated 22 August 2002 from present opponent			
	opposition proceedings against EP 0589 877	opposition proceedings against EP 0589 877		
C44	<u> Docoment 989 in Appeal No. To699/62-394. ⊙</u>	D's Willen Interlocator Decision in oppe	sillen pressedings.	
	Carcinos de mario de como de como como como como como como como com	against Enote 20 20		
C45	Document D90 in Appeal No. T0639/02-334: M	arvin & Hohn (1969). Bacteriological Rev	33(2), 172-209	
C46	Document D91 in Appeal No. T0639/02-334: Better et al. (1988). Science 240, 1041-1043			
C47	Document D92 in Appeal No. T0639/02-334: Sambrook & Russel (2001). Molecular cloning: a laboratory		ng: a laboratory	
	manual 3rd Edition, Cold Spring Harbor Press; particular pages 18.115 to 18.122 "Filamentous phage display"			
C48	Notice of Opposition to the European Patent EP-B-0589877 from Crucell Holland B.V, filed October 30 2002			
C49	Document D13: Communication of the European Office of 28 June 2001			
C50	Document D17: Vieira and Messing (1987), Me	thods Enzymol. 153, 3-11		
EXAMINER	Amber D. Steele/	DATE CO	Onsidered	
EXAMINF'	R: Initial if citation considered, whether or not citation			

PTO/SB/08A (10-0) Approved for use through 10/31/2002. OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet 6 Docket Number **Application Number** Substitute for form 1449A/PTO 05569.0004.DVUS11 **New Application** INFORMATION DISCLOSURE Applicant McCafferty et al. STATEMENT BY APPLICANT Filing Date (Use several sheets if necessary) Group Art Unit March 18, 2004 **OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.) C51 DUCUTTETT D27-Details of intermediate the control of the control Notice of Opposition to the European Patent EP 8 0607877 from Dyax Corp. C52 C53 Document Bt: EP Pregister print out for the patent application with file history interreption. no dates C54 Document DO: Claims filed with the divisional application C55 Document D7: Pluckthun and Skerra, "Expression of functional antibody Fv and Fab fragments in Escherichia coli," Methods in Enzymology, Vol. 178 (1989), pages 497-515 C56 Document D8: Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodology for displaying antibody (Fab) heavy and light chains," Nucleic Acids Research, Vol 19, No. 15 (1991), pages 4133-4137. C57 Notice of Opposition to the European Patent EP-B-0589877 from MorphoSys, filed October 30 2002 Document D1: Generalect, tis Patent Application 07/621:667; priority decoment to EP 92902109:5-C58 Opposition to European patent EP-B-0589877, cited opposition document D2: Nelson et al. "Filamentous C.59 DNA cloning vectors: a noninfective mutant with a nonpolar deletion in gene III", Virology 108: 338-350 (1981) Opposition to European patent EP-B-0589877, cited opposition document D3: McCoy and Khorana "Introduction and characterization of amber mutations in the bacteriorhodopsin gene", J. Bio. Chem. 258: 8456-8461 (1983) C61 Opposition to European patent EP-B-0589877, cited opposition document D5: Bullock et al. "XL1-blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection", Bio Techniques 5: 376-378 Opposition to European patent EP-B-0589877, cited opposition document D6: Schnee et al. "Construction C62 and expression of a recombinant antibody-targeted plasminogen activator", Proc. Natl. Acad. Sci. USA 84:6904-6908 (1987)**EXAMINER** /Amber D. Steele/

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in

Approved for use through 10/31/2002. OMB 0651-003 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless-it contains a valid OMB control number.

Sheet 7 of 1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Docket Number 05569.0004.DVUS11	Application Number New Application
		Applicant McCafferty et al.	
		Filing Date March 18, 2004	Group Art Unit
OTHER	R DOCUMENTS (Including Author, Title, Date,	Pertinent Pages, Etc.)	
C63	Opposition to European patent EP-B-058987 "Immunogenicity and epitope mapping of f	oreign sequences via genetic	
C64	Opposition to European patent EP-B-058987	comentous phage", J. Bio. Chem. 263: 4318-4322 (1988) Deposition to European patent EP-B-0589877, cited opposition document D15: Parmley and Smith Illamentous fusion phage cloning vectors for the study of epitopes and design of vaccines",	
C65	Opposition to European patent EP-B-0589877, cited opposition document D18: Chaudhary et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin", Nature 339: 394-397 (1989)		
C66	Opposition to European patent EP-B-0589877, cited opposition document D23: US 517 659 "Affymax priority document", entitled "Recombinant Library Screening Methods", priority document filed 1 May 1990 for EP-A-0 527 839 (Article 54(3) EPC)		
C67	Opposition to European patent EP-8-0589877, cited opposition document D26: Scott and Smith "Searching for peptide ligands with an epitope library", Science 249: 386-389 (1990)		
C68	Opposition to European patent EP-B-0589877, cited opposition document D27: Devlin et al. "Random peptid libraries: a source of specific protein binding molecules", Science 249: 404-405 (1990)		
C69	Opposition to European patent EP-B-0589877, cited opposition document D37: Markland et al. "Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13" Gene 109: 13-19 (1991)		
C70	Opposition to European patent EP-B-0589877, cited opposition document D38: Roberts et al. "Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage", Pro Natl. Acad. Sci. USA 89: 2429-2433 (1992)		
C71	Opposition to European patent EP-B-0589877, cited opposition document D39: Glockshuber et al. "The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli", Biochemistry 31: 1270-1279 (1992)		
C72	Opposition to European patent EP-B-0589877, cited opposition document D41: Kay et al. "Phage display of peptides and proteins", A laboratory Manual (1996) (Cover page and Foreward enclosed)		
C73	Opposition to European patent EP-B-0589877, cited opposition document D42: Proba et al. "A natural antibody		
	missing a cysteine in V_H : consequences for the $\{1997\}$	nermodynamic stability and fo	lding", J. Mol. Biol. 265: 161-172
EXAMINE	R /Amber D. Steele/		02/16/2010 SIDERED

Approved for use through 10/31/2002. OMB 0651-003 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE		Docket Number 05569.0004.DVUS11 Applicant	Application Numb New Applicati
(Lisa sav	STATEMENT BY APPLICANT eral sheets if necessary)	McCafferty et al. Filing Date	Group Art Unit
(036 364	erai sileets il fiecessary)	March 18, 2004	S.Gap. II. Gill.
OTHER	R DOCUMENTS (Including Author, Title, Date, Pe	ertinent Pages, Etc.)	
C74	Opposition to European patent EP-B-0589877,	cited opposition document D43: Prob	a et al. "Antibody scFv
_	fragments without disulfide bonds made by m	olecular evolution", J. Mol. Biol. 275: 24	5-253 (1998)
C75	Opposition to European patent EP-8-0589877,	cited opposition document D44: Lette	r of 18 November 199
	EPO from Kilburn Strode in prosecution of EP-B	-0 349 578	
C76	Opposition to European patent EP-B-0589877,	cited opposition document D45: Page	3 of EPO letter of 19
<u> </u>	October 1993 addressed to Plougmann, Ole (c/o Plougmann Vingtoft A/S) in prosecution of EP-B-0 768 377		
C77	Opposition to European patent EP-B-0589	877, cited opposition document D	46: Letter of 22
	September 1994 to EPO from Plougmann & Vingtoft in prosecution of EP-B-0 768 377		
C78	Opposition to European patent EP-B-0589877, cited opposition document D47: Extract from OD Decision in		
	opposition proceedings against EP-B-0 201 184, (1995)		
C79	Opposition to European patent EP-8-0589877, cited opposition document D48: Letter of 14 February 1996 to		
	EPO from Hepworth, Lawrence, Bryer & Bizley in prosecution of EP-A-0 527 839, 1996		
C80	Opposition to European patent EP-8-0589877, cited opposition document D49: the Boards of Appeal of the		
	European Patent Office decision of 8 May 1996, case number T694/92 – 3.3.4		
C81	Opposition to European patent EP-B-0589877, cited opposition document D50: Extract from opposition		
	proceeding against EP-B-0 349 578 (1996)		
C82	Opposition to European patent EP-B-0589877, cited opposition document D51: Extract from OD Decision in		
	proceedings against EP-B-0 349 578 (1998)		
C83	Opposition to European patent EP-8-0589877, cited opposition document D53: Declaration of professor sir Aaron		
	Klug, Ph.D. with exhibits, (23 June 1998)		
C84	Opposition to European patent EP & 0687877, eited opposition desument D64; proprint of paper by Seettle		
	Smith submitted to Science no dates		
C85	Opposition to European patent EP-8-0584877.	sited-apposition-decument-D55;-Smith.	grant-application
EXAMINE	I /Amber D. Steele/	, PAI	E CONSIDERED /2010
	// (III)Of D. O(OOIO/		/2010

Approved for use through 10/31/2002. OMB 0651-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet 9 of 1

Substitute for form 1449A/PTO		05569.0004.DVUS11	Application Num New Applica
	INFORMATION DISCLOSURE	Applicant	
	STATEMENT BY APPLICANT	McCafferty et al. Filing Date	. Croup Art Hoit
(Use several sheets if necessary)		March 18, 2004	Group Art Unit
OTHER	R DOCUMENTS (Including Author, Title, Date	, Pertinent Pages, Etc.)	
C86	Opposition to European patent EP-B-05898. September	77, late filed document D56: cla	im for infringement of 24
	1998, from Cambridge Antibody Technolog	gy Limited to EPO	
C87 Opposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Copposition to European patent EP-B-0589877, late filed document EP-B-0589877, late filed documen			Connell et al. "Constrained
	libraries as a tool for finding mimotopes", G	ene 151: 115-118 (1994).	
C88	Opposition to European patent EP-B-05898 Hendrix	77, late filed document D59: two	chapters of "Lambda II" (eds
	et al.) Cold Spring Harbour Laboratory, Col- Biology" (Arber) (pp. 381-395) and "Tail Ass		
C89	Opposition to European patent EP-B-05898.	77, late filed document D60: Par	mley & Smith "Filamentous fusi
	phage cloning vectors for the study of epitopes and design vaccines", Adv. Exp. Med. Biol. 251: 251-8 (198)		
C90	Opposition to European patent EP-B-0589877, late filed document D63: Declaration of William D. Huse, MI Ph.D. (17 August 1999		
C91	Opposition to European patent EP-B-0589877, late filed document D66: Crissman & Smith, "Gene-III protein filamentous phages: evidence for a carboxyl-terminal domain with a role in morphogenesis", Virology 132 445-455 (1994).		
C92	Opposition to European patent EP-B-05898. May, 2000)	77, late filed document D67: Dec	claration of Dr. Viia Valge-Arch
C93	Opposition to European patent EP-8-0589877, late filed document D68: Declaration of Dr. Hiroshi Ueda (3 May, 2000)		
C94	Opposition to European patent EP-B-0589877, late filed document D69: First Declaration of Dr. Rachel B. Ker (4 February, 2000).		
C95	Opposition to European patent EP-B-05898.	77, late filed document D71: lette	er of patentees filed at USPTO
-	16 July 1996.		
C96	Opposition to European patent EP-B-05898.	77, late filed document D72: lette	er of patentees filed at USPTO
	March 1997.		
C97	Opposition to European patent EP-8-05078	AGO::Ordenseasessessessessessessessessessessessess	oosition by Extragainst EP 80
	<i>53</i> 4÷		1
XAMINE	/Amber D. Steele/		DATE CONSIDERED 02/16/2010

Approved for use through 10/31/2002. OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		Dooket Number	January N		
Substitute for form 1449A/PTO		Docket Number 05569.0004.DVUS11	Application Number New Application		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant McCafferty et al.			
(Use seve	eral sheets if necessary)	Filing Date March 18, 2004	Group Art Unit		
OTHER	R DOCUMENTS (Including Author, Title, Date, Pe	ertinent Pages, Etc.)			
C98	Оррозініон то Евгоресан ротель ЕР-8-0500077,	- determined decomment D.74: Decisionet E 8			
C99	Opposition to European patent EP-B-0589877, late filed document D75: Declaration of Prof. Andreas Plückhun (3 May, 2000).				
C100	Opposition to European patent EP 8 0580877.	totofilod document D76: Natice of gran	ii.aassaaalita.Saiit h		
	grant application no date				
C101	Opposition to European patent EP-B-0589877, filamentous phage minor coat proteins in pho				
	document was objected to by patentees.				
C102	Opposition to European patent EP-8-0507077,	tale filed document 077. Extract from M	orphosys website .		
	no date				
C103	Opposition to European patent EP-B-0589877, to	late filed document D80: Written Decisio	on dated 26 May 2000		
	revoke EP-B-0436597.				
C104 .	Opposition to European patent EP-B-0589877,	Opposition to European patent EP-B-0589877, late filed document D81: 2nd Declaration of Dr. Viia Valge-			
	Archer (31 May, 2000).				
C105					
C106					
C107					
C108					
. C109					
1					
EXAMINER	R /Amber D. Steele/	02/16/21	CONSIDERED 010		
EXAMINE	R: Initial if citation considered, whether or not citation and not considered. Include copy of this form with no	is in conformance with MPEP § 609; Draw line	through citation if not in		